Episode
Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
- Podcast
- Hematologic Oncology Update
- Published
- Jul 22, 2026
- Duration seconds
- 7052
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/hematologic-oncology-update-916423/episodes/relapsed-refractory-multiple-myeloma-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/hematologic-oncology-update-916423/relapsed-refractory-multiple-myeloma-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Featuring perspectives from Dr Melissa Alsina, Dr Hans Lee, Dr Sagar Lonial and Dr Paul G Richardson, moderated by Dr Lonial, including the following topics: Introduction (0:00) Integrating Bispecific Antibodies into the Management of Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Lee (1:45) Current Utility of Antibody-Drug Conjugates for MM — Dr Lonial (33:55) Potential Role of Cereblon E3 Ligase Modulators in Therapy for MM — Dr Richardson (59:42) Chimeric Antigen Receptor T-Cell Therapy for R/R MM — Dr Alsina (1:30:24) CME information and select publications